News headlines about Oxford Immunotec Global (NASDAQ:OXFD) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oxford Immunotec Global earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.0925817003832 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
A number of equities research analysts have recently commented on OXFD shares. BTIG Research set a $21.00 target price on Oxford Immunotec Global and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Cowen reiterated a “buy” rating and set a $19.00 target price on shares of Oxford Immunotec Global in a research note on Thursday, September 28th. Robert W. Baird reiterated a “buy” rating and set a $20.00 target price on shares of Oxford Immunotec Global in a research note on Wednesday, November 1st. BidaskClub cut Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Saturday, December 9th. Finally, Zacks Investment Research lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Saturday, November 4th. Three analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Oxford Immunotec Global presently has a consensus rating of “Hold” and an average target price of $19.75.
Shares of Oxford Immunotec Global (NASDAQ OXFD) traded down $0.03 on Thursday, reaching $11.61. The company had a trading volume of 133,200 shares, compared to its average volume of 355,455. Oxford Immunotec Global has a 52 week low of $10.81 and a 52 week high of $19.51. The stock has a market cap of $298.62, a price-to-earnings ratio of -5.75 and a beta of -0.09. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.38.
In related news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total value of $40,050.00. Following the completion of the sale, the director now owns 17,778 shares of the company’s stock, valued at approximately $237,336.30. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 8.11% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Oxford Immunotec Global (OXFD) Given Daily Media Impact Score of 0.15” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.com-unik.info/2018/01/18/oxford-immunotec-global-oxfd-given-daily-media-impact-score-of-0-15.html.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.